U.S. Markets open in 6 hrs 51 mins
  • S&P Futures

    3,219.75
    -11.50 (-0.36%)
     
  • Dow Futures

    26,601.00
    -84.00 (-0.31%)
     
  • Nasdaq Futures

    10,766.75
    -62.25 (-0.57%)
     
  • Russell 2000 Futures

    1,445.90
    -0.80 (-0.06%)
     
  • Crude Oil

    39.62
    -0.31 (-0.78%)
     
  • Gold

    1,858.60
    -9.80 (-0.52%)
     
  • Silver

    22.23
    -0.88 (-3.79%)
     
  • EUR/USD

    1.1654
    -0.0008 (-0.0699%)
     
  • 10-Yr Bond

    0.6760
    0.0000 (0.00%)
     
  • Vix

    28.58
    +1.72 (+6.40%)
     
  • GBP/USD

    1.2693
    -0.0032 (-0.2539%)
     
  • BTC-USD

    10,320.96
    +71.49 (+0.70%)
     
  • CMC Crypto 200

    217.40
    +3.43 (+1.60%)
     
  • FTSE 100

    5,899.26
    +69.80 (+1.20%)
     
  • Nikkei 225

    23,087.82
    -258.67 (-1.11%)
     

Adaptive Biotechnologies to Present at the Morgan Stanley 2020 Healthcare Conference

Adaptive Biotechnologies

SEATTLE, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley Virtual Healthcare Conference.

Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Tuesday, September 15th at 10:15 a.m. Pacific Time / 1:15 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have two commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE MEDIA
Beth Keshishian
917-912-7195
media@adaptivebiotech.com

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
Carrie Mendivil, Gilmartin Group
investors@adaptivebiotech.com